Sorted By:

Relevance


Guest Post: Spotlighting the heroes in clinical trials

PhRMA  |  Blog Post

Every year, some 2 million people complete their participation in all sorts of research, part of their own hero's journey to seek wellness and contribute to science.
http://catalyst.phrma.org/guest-post-spotlighting-the-heroes-in-clinical-trials

What you need to know about access to innovative medicines in the U.S.

PhRMA  |  Blog Post

 Most cross-country comparisons focus solely on the list prices of medicines and ignore rebates negotiated by payers, as well as steep discounts required by U.S. public programs such as Medicaid and 340B.
http://catalyst.phrma.org/what-you-need-to-know-about-access-to-innovative-medicines-in-the-u.s

The Best Kind of Progress: Cancer Medicines and the Value They Bring to Us All

PhRMA  |  Blog Post

This can make medicines artificially appear to be the most expensive part of the health care system, when in fact they are delivering some of the best value to patients.
http://catalyst.phrma.org/the-best-kind-of-progress-cancer-medicines-and-the-value-they-bring-to-us-all

Never Too Late to Plan for Retirement

PhRMA  |  Blog Post

Specifically, I'm talking about coming to grips with potential chronic diseases like heart disease, diabetes and cancers, and doing more to treat these conditions before painful, expensive complications set it, or prevent them altogether.
http://catalyst.phrma.org/never-too-late-to-plan-for-retirement

Five Facts About the Value of Innovative Cancer Medicines

PhRMA  |  Blog Post

[12] 5.
http://catalyst.phrma.org/five-facts-about-the-value-of-innovative-cancer-medicines

PDUFA

PhRMA  |  From PhRMA

In 1992, Congress passed the first PDUFA to meet urgent patient demands for more timely approvals of life-saving treatments and cures.
https://www.phrma.org/advocacy/research-development/pdufa

Medicare Monday: Why imposing Medicaid-style rebates in Part D is a bad idea

PhRMA  |  Blog Post

In case you missed it, nearly 400 groups across the health care industry sent a letter to Congress last session opposing this exact proposal.
http://catalyst.phrma.org/medicare-monday-why-imposing-medicaid-style-rebates-in-part-d-is-a-bad-idea

Senior Director – State Policy (Pacific Northwest Region)

PhRMA  |  PhRMA Career

Professional Experience / Requirements Bachelor’s degree in Public Policy, Health Policy, Political Science, Public Affairs, or another field;  5+ years of progressive experience in state government affairs and/or within state government, legislature, regulatory, or executive branch; Previous experience analyzing policy and developing policy-related action plans; Previous experience working with state health care issues affecting the biopharmaceutical industry; Working knowledge of state health care issues affecting the biopharmaceutical industry; Must be willing to travel (up to 50% of the time during certain times of the year) and be responsive and available after hours and on weekends as needed; must have a valid driver’s license; Be an adaptable, creative problem solver, who is comfortable working in a high-pressure environment;  Excellent interpersonal skills that foster the ability to manage multiple projects simultaneously and meet short non-negotiable timelines.
https://www.phrma.org/careers/senior-director-state-policy-pacific-northwest-region

Week in Review: The Latest from PhRMA

PhRMA  |  Blog Post

Xian Shen, a 2015 PhRMA Foundation Young Investigator Adherence grantee, shared insights on the research she is doing to better understand medication adherence among Medicare beneficiaries.
http://catalyst.phrma.org/week-in-review-the-latest-from-phrma-june-19-2015

The R&D Challenges in tackling Ebola

PhRMA  |  Video

This IFPMA video interview with Ripley Ballou, who's in charge of GlaxoSmithKline's (GSK’s) Ebola vaccine program in Rixensart, Belgium, was recorded soon after Ebola scientists and representatives from companies and regulatory bodies met at the World Health Organization’s (WHO’s) headquarters in Geneva, Switzerland, 4-5 September, to discuss how to speed up clinical development of vaccines, a process that normally takes years.
https://www.phrma.org/video/the-randd-challenges-in-tackling-ebola

Case Study: How one online pharmacy knowingly endangered U.S. consumers

PhRMA  |  Blog Post

They could be stored improperly at the wrong temperature; they could be replaced with imitations that look the same but are instead contaminated with unsafe materials like road paint or drywall; or they could be expired with the dates altered to seem valid but the potency may vary dramatically as a result.
http://catalyst.phrma.org/case-study-how-one-online-pharmacy-knowingly-endangered-u.s.-consumers

Special Edition Medicare Monday: More context on MedPAC’s analysis of drug costs – Part II

PhRMA  |  Blog Post

In sum, even if numbers seem to speak for themselves, they rarely do.
http://catalyst.phrma.org/special-edition-medicare-monday-more-context-on-medpacs-analysis-of-drug-costs-part-ii

How do multiple sclerosis patients define value?

PhRMA  |  Blog Post

ICER’s assessment focuses on the cost-effectiveness and short-term budget impact of an MS treatment.
http://catalyst.phrma.org/how-do-multiple-sclerosis-patients-define-value

Hansen: Methodist Hospital cancer center patients now greeted with a story — how one man beat an 'incurable' prognosis

From Hope To Cures  |  From Our Network

” Then Jon takes off a pin he’s wearing on his shirt, near his heart.
http://www.fromhopetocures.org/hansen-methodist-hospital-cancer-center-patients-now-greeted-with-a-story-how-one-man-beat-an-incurable-prognosis

Associate Vice President – Science and Regulatory Advocacy (Biologics and Biosimilars Advocacy)

PhRMA  |  PhRMA Career

Accordingly, the successful candidate should be adaptable, able to reprioritize and shift gears quickly, comfortable in a high-pressure environment and be politically savvy, responsive, and mature.  
https://www.phrma.org/careers/associate-vice-president-science-and-regulatory-advocacy-biologics-and-biosimilars-advocacy

Week in Review: The Latest from PhRMA

PhRMA  |  Blog Post

Castellani sent a statement for the record to the Energy and Commerce Health Subcommittee on the hearing being held on the 340B program.
http://catalyst.phrma.org/week-in-review-the-latest-from-phrma-march-27-2015

Diabetes under the Dome

PhRMA  |  Blog Post

If you see physical changes in you or your children, check it out.
http://catalyst.phrma.org/diabetes-under-the-dome

Putting the IMS Health Global Forecast on Prescription Medicines in Perspective

PhRMA  |  Blog Post

And every additional dollar spent on medicines for adherent patients with congestive heart failure, high blood pressure, diabetes and high cholesterol generated $3 to $10 dollars in savings on emergency room visits and inpatient hospitalizations.
http://catalyst.phrma.org/putting-the-ims-health-global-forecast-on-prescription-medicines-in-perspective

Comparative Clinical Effectiveness Research Provision An Important Step Forward for Patient Care

PhRMA  |  Press Release

"We look forward to working with members of Congress as a long-term framework for comparative clinical effectiveness research is established, following the short-term appropriation of funds by the stimulus bill."
https://www.phrma.org/press-release/comparative-clinical-effectiveness-research-provision-an-important-step-forward-for-patient-care

Outdated FDA Regulations Discourage Development and Dissemination of Healthcare Economic Data to Support Value-Based Healthcare

PhRMA  |  Blog Post

”   As the biopharmaceutical industry endeavors to advance and embrace 21st century science, governing regulations are preventing the industry from supporting the shift to value-based healthcare.
http://catalyst.phrma.org/outdated-fda-regulations-discourage-development-and-dissemination-of-healthcare-economic-data-to-support-value-based-healthcare

YMCA Healthy Kids Day: Promoting Childhood Wellness

PhRMA  |  Blog Post

Measles has seen a resurgence in the United States because parents have listened to inaccurate rumors suggesting potentially harmful side effects among other factors.
http://catalyst.phrma.org/ymca-healthy-kids-day-promoting-childhood-wellness

Week in Review: The latest from PhRMA

PhRMA  |  Blog Post

Learn more about the importance of not rushing the TIPP negotiations to meet arbitrary deadlines that could put the United States at a disadvantage and result in a weak agreement.
http://catalyst.phrma.org/week-in-review-the-latest-from-phrma-april-29-2016

PhRMA Statement on Commissioner Scott Gottlieb’s Address to the Regulatory Affairs Professionals Society 2017 Regulatory Conference

PhRMA  |  Press Release

Food and Drug Administration (FDA) Commissioner Scott Gottlieb’s address to the Regulatory Affairs Professionals Society 2017 Regulatory Conference: “While the pace of science has evolved considerably, the simple fact is from drug discovery through U.S.
https://www.phrma.org/press-release/phrma-statement-on-commissioner-scott-gottlieb-s-address-to-the-regulatory-affairs-professionals-society-2017-regulatory-conference

Science of Hope: Learning from setbacks

PhRMA  |  Blog Post

The chance to interact with these oncology patients helps her feel more connected to the patients she is helping and reminds her of the importance of her work every day in the lab.
http://catalyst.phrma.org/science-of-hope-learning-from-setbacks

This Week on the Blogosphere

PhRMA  |  Blog Post

We'd love to see.
http://catalyst.phrma.org/this-week-on-the-blogosphere

You have reviewed the first 450 results out of 1200. Each page contains 25 results. You're on page 18.

prev 13 14 15 16 17 18 next